As one of the most important estimators in classical statistics, the uniformly minimum variance unbiased estimator (UMVUE) has been adopted for point estimation in many statistical studies, especially for small sample problems. Moving beyond typical settings in the exponential distribution family, it is usually challenging to prove the existence and further construct such UMVUE in finite samples. For example in the ongoing Adaptive COVID-19 Treatment Trial (ACTT), it is hard to characterize the complete sufficient statistics of the underlying treatment effect due to pre-planned modifications to design aspects based on accumulated unblinded data. As an alternative solution, we propose a Deep Neural Networks (DNN) guided ensemble learning framework to construct an improved estimator from existing ones. We show that our estimator is consistent and asymptotically reaches the minimal variance within the class of linearly combined estimators. Simulation studies are further performed to demonstrate that our proposed estimator has considerable finite-sample efficiency gain. In the ACTT on COVID-19 as an important application, our method essentially contributes to a more ethical and efficient adaptive clinical trial with fewer patients enrolled.
翻译:作为古典统计中最重要的估计者之一,在许多统计研究中,特别是对于小型抽样问题,都采用了统一的最低差异无偏差估计标准(UMVUE),以进行点估。超越指数分布系的典型环境,通常很难证明这种UMVUE在有限样本中的存在和进一步建造。例如,在正在进行的适应COVID-19治疗试验中,很难说明由于预先计划对基于累积的无盲数据的设计方面进行修改而对基本治疗效果所作的完整充分统计。作为一种替代办法,我们提议建立一个深神经网络(DNN)指导的混合学习框架,以从现有样本中建立一个更好的估计框架。我们表明,我们的估计者在线性综合估计者类别中达到最小的差异。还进行了模拟研究,以证明我们提议的估计者具有相当有限的效率收益。在COVID-19应用的ACT中,我们的方法基本上有助于对注册的病人进行更符合道德和高效的临床调整试验。